Briefing
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (PERSEUS)
Phase 3 trial, 709 transplant-eligible NDMM patients randomized to D-VRd (with D-R maintenance) vs VRd (with R maintenance). At median follow-up 47.5 months, 48-month PFS was 84.3% vs 67.7% (HR 0.42, 95% CI 0.30-0.59, P<0.001). CR or better 87.9% vs 70.1% (P<0.001); MRD-negative status 75.2% vs 47.5% (P<0.001). MRD analysis of an RCT (level 2), not MRD-guided therapy.
- Design: paper
- n: 709
- Assay: MRD negativity as a key secondary endpoint (threshold as prespecified in the protocol; reported as MRD-negative status)